货号:A161005
同义名:
β-桧木醇
/ β-Thujaplicin; NSC 18804
Hinokitiol是一种天然存在的单萜酚,具有抗氧化、抗菌、抗炎和抗肿瘤活性,可调节铁代谢并通过降低 Nrf2 的表达影响 DNA 甲基化相关蛋白的表达。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Ca2+ channel-like protein ↓ ↑ | Calcium Channel ↓ ↑ | Cav 2.2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDC25B-IN-2 | ✔ | Akt | 99%+ | ||||||||||||||||
| Clevidipine | ✔ | 97% | |||||||||||||||||
| Verapamil HCl | ✔ | 99% | |||||||||||||||||
| Amlodipine | ✔ | 99% | |||||||||||||||||
| Amlodipine maleate | ✔ | 98% | |||||||||||||||||
| (+)-cis-Diltiazem HCl | ✔ | 99% | |||||||||||||||||
| Zegocractin |
++
Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM |
99%+ | |||||||||||||||||
| Tanshinone IIA sulfonate sodium | ✔ | 98% | |||||||||||||||||
| Ulixacaltamide |
++
hCaV3.1, IC50: 50 nM hCaV3.2, IC50: 110 nM |
99%+ | |||||||||||||||||
| Dronedarone HCl | ✔ | 95% | |||||||||||||||||
| Nitrendipine |
+
Calcium channel, IC50: 95 nM |
98% | |||||||||||||||||
| Efonidipine HCl monoethanolate | ✔ | 98% | |||||||||||||||||
| Cinnarizine | ✔ | 98% | |||||||||||||||||
| SEA0400 |
++
NCX, IC50: 33 nM |
ERK,ROS,p38 MAPK | 99%+ | ||||||||||||||||
| Fasudil HCl | ✔ | Rho,PKA | 98% | ||||||||||||||||
| ML-9 | ✔ | MLCK,Akt | 99%+ | ||||||||||||||||
| Flunarizine 2HCl |
+
Calcium channel, Ki: 68 nM |
95% | |||||||||||||||||
| Lomerizine 2HCl | ✔ | 98% | |||||||||||||||||
| Efonidipine | ✔ | 98% | |||||||||||||||||
| Levamlodipine | ✔ | 98% | |||||||||||||||||
| Nisoldipine |
++
L-type Cav1.2, IC50: 10 nM |
97% | |||||||||||||||||
| Isradipine | ✔ | 98% | |||||||||||||||||
| Lacidipine | ✔ | 98% | |||||||||||||||||
| Lercanidipine | ✔ | 99% | |||||||||||||||||
| Loureirin B | ✔ | Potassium Channel | 99%+ | ||||||||||||||||
| Tetracaine HCl | ✔ | 98% | |||||||||||||||||
| Manidipine |
+++
Calcium channel, IC50: 2.6 nM |
99% | |||||||||||||||||
| Manidipine Dihydrochlorid |
+++
Calcium channel, IC50: 2.6 nM |
98% | |||||||||||||||||
| Nicardipine | ✔ | 99% | |||||||||||||||||
| Wilforgine | ✔ | 98+% | |||||||||||||||||
| Econazole | ✔ | 99%+ | |||||||||||||||||
| Ginsenoside Rd | ✔ | NF-κB | 98% | ||||||||||||||||
| Fendiline HCl | ✔ | 98+% | |||||||||||||||||
| Mesaconitine | ✔ | 98% | |||||||||||||||||
| Tetrandrine | ✔ | 95% | |||||||||||||||||
| Nifedipine | ✔ | 98% | |||||||||||||||||
| Nilvadipine |
++++
Calcium channel, IC50: 0.03 nM |
95% | |||||||||||||||||
| Barnidipine |
++++
[3H]nitrendipine, Ki: 0.21 nM |
95+% | |||||||||||||||||
| Azelnidipine | ✔ | 97% | |||||||||||||||||
| Levetiracetam | ✔ | 98% | |||||||||||||||||
| Nimodipine | ✔ | 95% | |||||||||||||||||
| Benidipine HCl | ✔ | 98% | |||||||||||||||||
| Pinaverium bromide | ✔ | 98% | |||||||||||||||||
| Pranidipine | ✔ | 99% | |||||||||||||||||
| NP118809 |
+
L-type calcium channel, IC50: 12.2 μM N-type Ca2+ channel, IC50: 0.11 μM |
95% | |||||||||||||||||
| Amlodipine Besylate |
+++
Calcium channel, IC50: 1.9 nM |
97% | |||||||||||||||||
| Cilnidipine | ✔ | 99% | |||||||||||||||||
| Cinepazide Maleate | ✔ | 99% (HPLC) | |||||||||||||||||
| Terfenadine | ✔ | 98% | |||||||||||||||||
| YM-58483 | ✔ | 99%+ | |||||||||||||||||
| Amiloride HCl | ✔ | 98% | |||||||||||||||||
| Ranolazine | ✔ | 98% | |||||||||||||||||
| Praeruptorin A | ✔ | Akt,p38 MAPK | 98% | ||||||||||||||||
| Ranolazine 2HCl | ✔ | 98% | |||||||||||||||||
| Felodipine |
++++
L-type calcium channel, IC50: 0.15 nM |
98% | |||||||||||||||||
| PD173212 |
+++
N-type Ca2+ channel, IC50: 36 nM |
98% | |||||||||||||||||
| Levamlodipine besylate | ✔ | 97% | |||||||||||||||||
| Carboxyamidotriazole Orotate | ✔ | 98% | |||||||||||||||||
| IGS-1.76 | ✔ | 98+% | |||||||||||||||||
| WH-4-023 |
++++
Cav 2.2, IC50: 0.001 μM |
++++
Cav 2.2, IC50: 0.001 μM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Hinokitiol, a tropolone-related natural compound, is known to induce apoptosis and cell cycle arrest and has anti-inflammatory and anti-tumor activities. Hinokitiol may exert DNA demethylation by inhibiting the expression of DNMT1 (DNA methyltransferase 1) and UHRF1 (RING finger domain 1) in colon cancer cells[3]. In U87MG and T98G glioma cell lines, hinokitiol demonstrates a dose-dependent decrease in viability, with IC50 values of 316.5 ± 35.5 and 152.5 ± 25.3 µM, respectively. Hinokitiol represses ALDH activity and self-renewal ability in glioma stem cells, and inhibits in vitro oncogenicity. Hinokitiol also reduces Nrf2 expression in glioma stem cells in a dose-dependent manner[4]. Hinokitiol attenuates liver injury following HS/R (Haemorrhagic shock and resuscitation), partly through the inhibition of NF-κB activation[5]. Moreover, hinokitiol inhibited the migration of lung cancer A549 cells through several mechanisms, including the activation of caspases-9 and -3, induction of p53/Bax and antioxidant CAT (antioxidant enzymes catalase) and SOD (superoxide dismutase), and reduction of MMP-2 and -9 (matrix metalloproteinases) activities. It also induces cytochrome c expression[6]. |
| Concentration | Treated Time | Description | References | |
| FPN1-deficient J774 macrophages | 1 μM | Restored iron release in FPN1-deficient cells | Science. 2017 May 12;356(6338):608-616 | |
| PANC-1 human pancreatic cancer cells | 80 μg/mL | 10 h | To evaluate the effect of Hinokitiol on iron content and mitochondrial function in mammalian cells. Results showed that Hinokitiol had minor effects on iron content and mitochondrial function in mammalian cells, indicating selectivity towards fungal cells. | J Adv Res. 2021 Jun 17;34:65-77 |
| BEAS-2B human bronchial epithelial cells | 80 μg/mL | 10 h | To evaluate the effect of Hinokitiol on iron content and mitochondrial function in mammalian cells. Results showed that Hinokitiol had minor effects on iron content and mitochondrial function in mammalian cells, indicating selectivity towards fungal cells. | J Adv Res. 2021 Jun 17;34:65-77 |
| Candida albicans SC5314 | 2-8 μg/mL | 30 min to 10 h | To evaluate the effect of Hinokitiol on fungal intracellular iron content and its inhibition of mitochondrial respiration. Results showed that Hinokitiol significantly reduced intracellular Fe2+ levels, inhibited the activities of mitochondrial respiratory chain complexes I and II, leading to decreased mitochondrial membrane potential and ATP production. | J Adv Res. 2021 Jun 17;34:65-77 |
| Mfrn1-deficient MEL cells | 1 μM | Restored iron uptake and hemoglobinization in Mfrn1-deficient cells | Science. 2017 May 12;356(6338):608-616 | |
| DS19 murine erythroleukemia (MEL) cells | 1 μM | 3 days | Restored iron uptake, iron-heme incorporation, and hemoglobinization in DMT1-deficient cells | Science. 2017 May 12;356(6338):608-616 |
| Caco-2 gut epithelial cells | 500 nM | Restored iron uptake and transepithelial iron transport in DMT1-deficient monolayers | Science. 2017 May 12;356(6338):608-616 | |
| Kupffer cells | 5 μM | 60 minutes | restore iron transport and reduce intracellular iron accumulation | Proc Natl Acad Sci U S A. 2022 Jun 28;119(26):e2121400119 |
| RAW264.7 macrophages | 5 μM | assess iron release and intracellular labile iron levels | Proc Natl Acad Sci U S A. 2022 Jun 28;119(26):e2121400119 | |
| HL-7702 cells | 25, 50, 100, 200, 400 nM | 24, 48, 72 hours | To evaluate the cytotoxicity of β-Thujaplicin on normal liver cells, results showed that β-Thujaplicin had minimal effect on the growth of HL-7702 cells | Cell Death Dis. 2019 Mar 15;10(4):255 |
| HCCLM3 cells | 25, 50, 100, 200, 400 nM | 24, 48, 72 hours | To evaluate the cytotoxicity of β-Thujaplicin on HCC cells, results showed that β-Thujaplicin significantly inhibited the growth of HCCLM3 cells in a dose-dependent manner | Cell Death Dis. 2019 Mar 15;10(4):255 |
| SMMC-7721 cells | 25, 50, 100, 200, 400 nM | 24, 48, 72 hours | To evaluate the cytotoxicity of β-Thujaplicin on HCC cells, results showed that β-Thujaplicin significantly inhibited the growth of SMMC-7721 cells in a dose-dependent manner | Cell Death Dis. 2019 Mar 15;10(4):255 |
| HepG2 cells | 25, 50, 100, 200, 400 nM | 24, 48, 72 hours | To evaluate the cytotoxicity of β-Thujaplicin on HCC cells, results showed that β-Thujaplicin significantly inhibited the growth of HepG2 cells in a dose-dependent manner | Cell Death Dis. 2019 Mar 15;10(4):255 |
| CRL-8024 cells | 10–100μM | To evaluate the effect of hinokitiol on HCC cell proliferation, results showed that hinokitiol significantly attenuated the proliferation of HCC cell lines in a dose-dependent manner while downregulating the protein levels of UHRF1, GLI1, CD44, and CD133. | Cell Death Dis. 2023 Jun 28;14(6):381 | |
| MEL cells | 1 μM | probe hemoglobinization and iron uptake | Proc Natl Acad Sci U S A. 2022 Jun 28;119(26):e2121400119 | |
| MDA-MB-231 cells | 6.25 to 100 µg/mL | 48 hours | To evaluate anticancer efficacy, results showed that Hinokitiol-loaded phytosomal formulation had higher cytotoxicity than pure Hinokitiol, with an IC50 value of 5.7 µg/mL | Int J Nanomedicine. 2024 Oct 12;19:10321-10339 |
| MCF-7 cells | 6.25 to 100 µg/mL | 48 hours | To evaluate anticancer efficacy, results showed that Hinokitiol-loaded phytosomal formulation had higher cytotoxicity than pure Hinokitiol, with an IC50 value of 18.6 µg/mL | Int J Nanomedicine. 2024 Oct 12;19:10321-10339 |
| normal liver cell line HL-7702 | 25, 50, 100, 200, 400 nM | 24, 48, 72 h | To evaluate the effect of β-Thujaplicin on normal liver cells, results showed that β-Thujaplicin had only a slight effect on the viability of HL-7702 cells at 400 nM | Cell Death Dis. 2019 Mar 15;10(4):255. |
| human hepatoma cell lines HCCLM3 | 25, 50, 100, 200, 400 nM | 24, 48, 72 h | To evaluate the inhibitory effect of β-Thujaplicin on HCC cell growth, results showed that β-Thujaplicin significantly inhibited the viability of HCCLM3 cells in a dose-dependent manner | Cell Death Dis. 2019 Mar 15;10(4):255. |
| human hepatoma cell lines SMMC-7721 | 25, 50, 100, 200, 400 nM | 24, 48, 72 h | To evaluate the inhibitory effect of β-Thujaplicin on HCC cell growth, results showed that β-Thujaplicin significantly inhibited the viability of SMMC-7721 cells in a dose-dependent manner | Cell Death Dis. 2019 Mar 15;10(4):255. |
| human hepatoma cell lines HepG2 | 25, 50, 100, 200, 400 nM | 24, 48, 72 h | To evaluate the inhibitory effect of β-Thujaplicin on HCC cell growth, results showed that β-Thujaplicin significantly inhibited the viability of HepG2, SMMC-7721, and HCCLM3 cells in a dose-dependent manner | Cell Death Dis. 2019 Mar 15;10(4):255. |
| Administration | Dosage | Frequency | Description | References | ||
| Galleria mellonella | Candida albicans-infected larvae | Injection | 2 μg/larva | Single dose, observed for 7 days | To evaluate the therapeutic effect of Hinokitiol on Candida albicans infection in vivo. Results showed that Hinokitiol significantly improved the survival rate of infected larvae and reduced fungal burden. | J Adv Res. 2021 Jun 17;34:65-77 |
| Belgrade rats | DMT1-deficient rat model | Oral gavage | 1.5 mg/kg | Single dose | Promoted gut iron absorption in DMT1-deficient rats | Science. 2017 May 12;356(6338):608-616 |
| Nude mice | HepG2 tumor xenograft model | Intraperitoneal injection | 5 mg/kg body weight | Once daily for 15 days | To evaluate the inhibitory effect of β-Thujaplicin on HepG2 tumor growth in vivo, results showed that β-Thujaplicin significantly reduced tumor volume and weight | Cell Death Dis. 2019 Mar 15;10(4):255 |
| Mice | Myc-driven HCC model | Intraperitoneal injection | 25 mg/kg | Twice a week from 4 to 9 weeks of birth | To evaluate the effect of hinokitiol on Myc-driven HCC mouse model, results showed that hinokitiol significantly reduced tumor growth and CSC phenotypes, and downregulated the expression of UHRF1, GLI1, CD44, and CD133. | Cell Death Dis. 2023 Jun 28;14(6):381 |
| Mice | FPN1-deficient mice | Intraperitoneal injection | 10 mg/kg | Daily for 1 week | Restore hemoglobinization and iron distribution | Proc Natl Acad Sci U S A. 2022 Jun 28;119(26):e2121400119 |
| Nude mice | HepG2 tumor xenograft model | Intraperitoneal injection | 5 mg/kg body weight | Once daily for 15 days | To verify the antitumor effect of β-Thujaplicin in vivo, results showed that β-Thujaplicin significantly inhibited the growth of HepG2 tumor xenografts | Cell Death Dis. 2019 Mar 15;10(4):255. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
6.09mL 1.22mL 0.61mL |
30.45mL 6.09mL 3.05mL |
60.90mL 12.18mL 6.09mL |
|
| CAS号 | 499-44-5 |
| 分子式 | C10H12O2 |
| 分子量 | 164.2 |
| SMILES Code | O=C1C(O)=CC(C(C)C)=CC=C1 |
| MDL No. | MFCD00040180 |
| 别名 | β-桧木醇 ;β-Thujaplicin; NSC 18804; 4-Isopropyltropolone |
| 运输 | 蓝冰 |
| InChI Key | FUWUEFKEXZQKKA-UHFFFAOYSA-N |
| Pubchem ID | 3611 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(639.46 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1